1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

AstraZeneca wins EU approval of Axanum for CV prevention in those at gastric risk

 
• By Pial Ganguli

AstraZeneca’s fixed-dose combination therapy, Axanum (esomeprazole plus low dose aspirin), has received positive agreement for approval in 23 European Union member countries and in Norway for the prevention of cardiovascular (CV) events in high-risk patients who require daily low-dose aspirin treatment but are also at risk of gastric ulcers.

AstraZeneca’s fixed-dose combination therapy, Axanum (esomeprazole plus low dose aspirin), has received positive agreement for approval in 23 European Union member countries and in Norway for the prevention of cardiovascular (CV) events in high-risk patients who require daily low-dose aspirin treatment but are also at risk of gastric ulcers.

The EU decision took place under the decentralised procedure, with Germany acting as reference member state. This process will now...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from Therapeutic Category

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?